Simulations Plus Inc (OQ:SLP)

Business Focus: Medical Software & Technology Services

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 42505 10Th Street West
LANCASTER CA 93534-7059
Tel: 1-661-7237723
Website: https://www.simulations-plus.com
IR: See website
<
Key People
Shawn M. O'Connor
Chief Executive Officer
William Frederick
Chief Financial Officer, Chief Operating Officer, Secretary
John A. Dibella
President - PBPK, Regulatory Strategies, Cheminformatics Solutions
Jill Fiedler-Kelly
President - Clinical Pharmacology and Pharmacometric Services
Brett Howell
President - Quantitative Systems Pharmacology Solutions
Sandra Suarez Sharp
President - Regulatory Strategies
Dan Szot
Chief Revenue Officer
   
Business Overview
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.
Financial Overview
For the six months ended 29 February 2024, Simulations Plus Inc revenues increased 18% to $32.8M. Net income increased 10% to $6M. Revenues reflect Software segment increase of 16% to $19.2M, Services segment increase of 22% to $13.6M, Americas segment increase of 22% to $23.4M, Europe segment increase of 21% to $7M. Net income was partially offset by Change in fair valuation of contingent c increase from $0K to $330K (expense).
Employees: 192 as of Aug 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $779.03M as of Feb 29, 2024
Annual revenue (TTM): $64.67M as of Feb 29, 2024
EBITDA (TTM): $13.39M as of Feb 29, 2024
Net annual income (TTM): $10.52M as of Feb 29, 2024
Free cash flow (TTM): $7.97M as of Feb 29, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 19,984,945 as of Mar 31, 2024
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.